Skip to Content
Merck
CN
  • Additive Manufacturing of Personalized Pharmaceutical Dosage Forms via Stereolithography.

Additive Manufacturing of Personalized Pharmaceutical Dosage Forms via Stereolithography.

Pharmaceutics (2019-12-11)
Andrew V Healy, Evert Fuenmayor, Patrick Doran, Luke M Geever, Clement L Higginbotham, John G Lyons
ABSTRACT

The introduction of three-dimensional printing (3DP) has created exciting possibilities for the fabrication of dosage forms, paving the way for personalized medicine. In this study, oral dosage forms of two drug concentrations, namely 2.50% and 5.00%, were fabricated via stereolithography (SLA) using a novel photopolymerizable resin formulation based on a monomer mixture that, to date, has not been reported in the literature, with paracetamol and aspirin selected as model drugs. In order to produce the dosage forms, the ratio of poly(ethylene glycol) diacrylate (PEGDA) to poly(caprolactone) triol was varied with diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide (Irgacure TPO) utilized as the photoinitiator. The fabrication of 28 dosages in one print process was possible and the printed dosage forms were characterized for their drug release properties. It was established that both drugs displayed a sustained release over a 24-h period. The physical properties were also investigated, illustrating that SLA affords accurate printing of dosages with some statistically significant differences observed from the targeted dimensional range, indicating an area for future process improvement. The work presented in this paper demonstrates that SLA has the ability to produce small, individualized batches which may be tailored to meet patients' specific needs or provide for the localized production of pharmaceutical dosage forms.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide, 97%